

# Effect of Renin-Angiotensin System Blockade on Insulin Resistance and Inflammatory Parameters in Patients With Impaired Glucose Tolerance

STEFAN PSCHERER, MD<sup>1</sup>  
 UWE HEEMANN, MD<sup>2</sup>  
 HELGA FRANK, MD<sup>2</sup>

**OBJECTIVE**— The study investigated the effect of angiotensin receptor blockers (ARB) on glucose homeostasis and inflammatory parameters in patients with impaired glucose tolerance (IGT).

**RESEARCH DESIGN AND METHODS**— We prospectively studied the insulin sensitivity index (ISI) and homeostasis model assessment–insulin resistance (HOMA-IR) in 13 obese males with IGT and in 13 matched control subjects with normal glucose tolerance (NGT) during hyperglycemic testing over 90 min. Adiponectin, retinol-binding protein 4 (RBP4), and high-sensitive C-reactive protein (hsCRP) were analyzed. Measurements were performed at baseline and after a 4-week treatment with 160 mg/day valsartan. The results of the IGT and NGT groups were compared.

**RESULTS**— At baseline, HOMA-IR (IGT  $4.1 \pm 3$  vs. NGT  $2.3 \pm 1.0$ ,  $P < 0.01$ ), hsCRP (IGT  $3.9 \pm 1.9$  vs. NGT  $1.8 \pm 1$  mg/l,  $P < 0.05$ ), and RBP4 (IGT  $27.1 \pm 2.1$  vs. NGT  $24.0 \pm 2.0$  ng/ml,  $P < 0.05$ ) were significantly higher, whereas ISI (IGT  $1.5 \pm 0.9$  vs. NGT  $1.8 \pm 1.2$ ,  $P < 0.05$ ) and plasma adiponectin (IGT  $3.2 \pm 0.9$ , NGT  $5.2 \pm 2.4$   $\mu$ g/ml,  $P < 0.05$ ) were significantly lower in the IGT group compared with the NGT group. Under ARB, there was an increase in both groups of adiponectin (IGT  $4.1 \pm 1.9$   $\mu$ g/ml, NGT  $6.3 \pm 2.9$   $\mu$ g/ml,  $P < 0.05$ ) and an increase in ISI (IGT  $1.5 \pm 0.9$  to  $2.3 \pm 1$   $\mu$ g/ml, NGT  $1.8 \pm 1$  to  $2.5 \pm 2$   $\mu$ g/ml,  $P < 0.05$ ). HOMA-IR ( $4.1 \pm 3$  to  $2.6 \pm 2$ ;  $P < 0.01$ ), hsCRP ( $3.9 \pm 1.9$  to  $1.8 \pm 1$  mg/l,  $P < 0.05$ ), and RBP4 ( $27.1 \pm 2.1$  to  $22.1 \pm 1.8$  ng/ml,  $P < 0.01$ ) decreased significantly in the IGT group.

**CONCLUSIONS**— Insulin sensitivity and associated inflammatory factors improve under ARB in IGT patients.

*Diabetes Care* 33:914–919, 2010

Insulin resistance has a causal role in type 2 diabetes, a crucial risk factor for cardiovascular and renal disease (1). Impaired glucose tolerance (IGT) represents an intermediate state of abnormal glucose regulation between normal glucose homeostasis and manifest diabetes. IGT is defined as elevated 2-h plasma glucose concentration  $>140$  and  $<200$  mg/dl after a 75-g oral glucose load in an oral glucose tolerance test (2). A combi-

nation of  $\beta$ -cell dysfunction and insulin resistance with decreased insulin sensitivity or responsiveness to the metabolic action of insulin plays a pathogenetic role. Insulin resistance is common in subjects with visceral adiposity, hypertension, hyperglycemia, and dyslipidemia. Patients with metabolic syndrome have a high risk of developing frank diabetes (3).

Adiponectin is a fat-derived hormone specifically produced and secreted by adi-

pocytes. This adipocytokine is considered an important modulator of insulin sensitivity in patients with IGT (4,5). Adiponectin levels decrease in the obese, which may be a contributing factor to insulin resistance. Anti-inflammatory properties also have been attributed to adiponectin. This is indicated by serum concentrations of adiponectin, which are inversely associated with inflammatory markers such as C-reactive protein (CRP). Retinol-binding protein 4 (RBP4) is another adipocyte-secreted molecule and is elevated in serum before development of overt diabetes (6).

The interaction of these different metabolic and inflammatory parameters in IGT has not been fully clarified. Our study investigates insulin sensitivity and associated risk factors focusing on obese subjects with IGT. We tested the effect of a short-term 4-week angiotensin receptor blocker (ARB) treatment on glucose disposal and inflammatory markers in subjects with IGT.

## RESEARCH DESIGN AND METHODS

### Study design

A total of 57 male adults with a waist circumference  $>102$  cm were tested. Screening included physical examination and blood and urine chemistry. IGT was diagnosed based on an oral glucose tolerance test (2). Smokers and patients with known vascular, infectious, or inflammatory diseases, micro- and macroalbuminuria, serum creatinine  $\geq 1.2$  mg/dl, secondary forms of or uncontrolled hypertension (greater than European Society of Hypertension class 1), ongoing medication with blockade of the renin-angiotensin system (RAS), and diabetes were excluded.

A total of 15 subjects had IGT, 3 subjects had diabetes, and 39 subjects had NGT. Thirteen subjects with IGT fulfilled all inclusion criteria and completed the entire study. We selected 13 tightly matched control subjects from the NGT group.

From the <sup>1</sup>Department of Nephrology and Diabetology, Klinikum Traunstein, Traunstein, Germany; and the <sup>2</sup>Department of Nephrology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany. Corresponding author: Helga Frank, helga.frank@lrz.tum.de.

Received 29 July 2009 and accepted 11 January 2010. Published ahead of print at <http://care.diabetesjournals.org> on 19 January 2010. DOI: 10.2337/dc09-1381. Clinical trial registry no.: ISRCTN07427212, [www.isrctn.org](http://www.isrctn.org).

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The 24-h blood pressure measurements were taken using an automated portable device at the beginning and end of the study (Spacelabs Medical, Redmond, WA). Measurements of the study parameters were performed at rest and during hyperglycemic stress testing at baseline (U1) and after a 4-week treatment with valsartan (U2).


The study was approved by the Ethical Committee of the Technical University of Munich. Every participant gave written informed consent. This investigator initiated trial was confirmed by the Federal Institute for Drugs and Medical Devices (BfArM, Germany) and registered by the European Clinical Trials Database (EudraCT, no. 2005-001278-28).

**Hyperglycemic clamp**

A modified clamp technique following the De Fronzo protocol was used to achieve a hyperglycemic level of a target blood glucose between 160 and 180 mg/dl (7). Initially, the subjects received an intravenous bolus of 1.5 ml 20% glucose solution/kg to raise plasma glucose acutely above 200 mg/dl. Plasma glucose concentrations during the procedure were monitored at 1-min intervals (glucose analyzer, HITADO Diagnostic Systems). When blood glucose reached a level of 180 mg/dl, the desired hyperglycemic plateau of >160 mg/dl and <180 mg/dl was maintained by initiating an adjusted continuous infusion of 20% glucose depending on the actual blood glucose concentration. Once a steady state was reached and maintained for over 90 min, laboratory parameters were measured (Fig. 1). Serum glucose, serum insulin, and C-peptide were measured after a 12-h fast at baseline.

**Laboratory methods**

Serum insulin concentrations were measured using electrochemiluminescence. Adiponectin plasma concentrations were determined by an enzyme-linked immunosorbent assay. RBP4 was measured using the Human RBP4 Quantikine ELISA Kit DRB400. All other measurements were performed with routine laboratory tests and methods certified by the Institute of Clinical Chemistry, Technical University Munich, Germany. Insulin sensitivity was quantified using the validated model of homeostasis model assessment–insulin resistance (HOMA-IR) (8). Insulin sensitivity index was calculated as



**Figure 1**—Experimental setting and course of blood glucose (mg/dl) during hyperglycemic stress testing by intravenous glucose infusion for each group without ARB. A bolus (1.5 ml 20% glucose solution/kg) was given to raise blood glucose acutely. Subsequently, as blood glucose reached a level of 180 mg/dl, the desired hyperglycemic plateau of >160 mg/dl and <180 mg/dl was maintained by the start of an adjusted continuous infusion of 20% glucose. There is a significant difference of the time duration to undercut a blood glucose value of 180 mg/dl with a significantly shorter time in the NGT group (Mann-Whitney U test; presented as box plots,  $P < 0.001$ , Bonferroni-adjusted P values).

$1/\text{fasting serum insulin} \times \text{fasting serum glucose}$  (9).

**Statistical analysis**

Data are given as means  $\pm$  SD for continuous variables or as a percentage in categorical variables. Normal data distribution was confirmed by the Kolmogorov-Smirnov test. Normally distributed data were analyzed using the Student's *t* test for comparisons at baseline and after treatment with ARB. We used the Mann-Whitney *U* test to analyze the differences


of time spent to undercut the target limit of 180 mg/dl blood glucose for both groups. All statistical analyses were performed using the SPSS version 16.0 for Windows.

**RESULTS**— Baseline characteristics are shown in Table 1. There was no significant difference in age, BMI, waist circumference, systolic and diastolic blood pressure, fasting serum glucose, triglycerides, and HDL cholesterol. A total of 13 participants were treated

**Table 1**—Baseline characteristics of the subjects according to the study groups

	IGT group	NGT group
<i>n</i>	13	13
Age (years)	50.0 $\pm$ 13	50.6 $\pm$ 10
BMI (kg/m <sup>2</sup> )	31.1 $\pm$ 6	33.5 $\pm$ 4
Waist circumference (cm)	110.3 $\pm$ 11	111.9 $\pm$ 9
Office systolic blood pressure (mmHg)	137 $\pm$ 10	136 $\pm$ 16
Office diastolic blood pressure (mmHg)	85 $\pm$ 6	88 $\pm$ 13
Fasting serum glucose (mg/dl)	89 $\pm$ 13	85 $\pm$ 8
Serum triglycerides (mg/dl)	111 $\pm$ 37	102 $\pm$ 37
Serum HDL (mg/dl)	45 $\pm$ 14	44 $\pm$ 16

Data are means  $\pm$  SD.



**Figure 2**—Blood glucose (mean values) (mg/dl) during hyperglycemic stress testing for each group after 4-week treatment with valsartan.

with antihypertensive agents (calcium antagonists: four IGT; three NGT;  $\beta$ -blockers: three IGT, three NGT). During hyperglycemia, mean blood glucose values of  $170 \pm 9$  mg/dl (IGT) and  $171 \pm 7$  mg/dl (NGT) were held over 90 min. The time required to reach steady-state conditions within the targeted blood glucose plateau was longer in the IGT group (IGT  $37.2 \pm 3$  vs. NGT  $15.8 \pm 2$  min,  $P < 0.05$ , Fig. 1). Under ARB, there was no significant difference in the blood glucose profiles of both study groups under clamp testing (Fig. 2). At baseline, HOMA-IR, RBP4, and high-sensitive (hs)-CRP serum levels

were significantly higher, whereas insulin sensitivity index and plasma adiponectin were significantly lower for the IGT group (Table 2). At baseline, in both groups, there were no significant differences in ambulatory systolic (IGT  $125 \pm 6$  vs. NGT  $123 \pm 1$  mmHg,  $P = 0.86$ ) and diastolic (IGT  $77 \pm 2$ ; NGT  $77 \pm 3$  mmHg,  $P = 0.95$ ) blood pressure. However, there was a significantly higher reduction of systolic blood pressure in the IGT group compared with the NGT group (IGT  $118 \pm 3$  vs. NGT  $121 \pm 4$  mmHg,  $P < 0.05$ ) under ARB. There was no significant difference between diastolic blood pressure re-

duction in either group (IGT  $73 \pm 3$  vs. NGT  $74 \pm 5$  mmHg,  $P = 0.11$ ) (Table 2).

#### Effects of ARB on insulin sensitivity

Under 4-week treatment with valsartan, insulin sensitivity index increased significantly in both groups (IGT  $1.5 \pm 1$  vs.  $2.3 \pm 1$ ,  $P < 0.05$ ; NGT  $1.8 \pm 1$  vs.  $2.5 \pm 2$ ,  $P < 0.05$ ). HOMA-IR decreased significantly in the IGT group under ARB (IGT  $4.1 \pm 3$  vs.  $2.6 \pm 2$ ,  $P < 0.01$ ; NGT  $2.3 \pm 1$  vs.  $1.6 \pm 1$ ,  $P = 0.016$ , Fig. 3). There was a significant reduction in A1C in the IGT group ( $5.58 \pm 0.15$  vs.  $5.2 \pm 0.25\%$ ,  $P < 0.05$ ), whereas no A1C changes were noted in the control group (Table 2). RBP4 decreased significantly in the IGT group (IGT  $27.1 \pm 2.1$  vs.  $22.1 \pm 1.8$  ng/ml,  $P < 0.01$ ; NGT  $24.0 \pm 2.0$  vs.  $22.0 \pm 1.9$ ,  $P = 0.98$ ). Fasting insulin levels were reduced under valsartan in both groups (IGT  $16.6 \pm 11$  vs.  $13.2 \pm 8$  mU/l,  $P < 0.05$ ; NGT  $16.1 \pm 10$  vs.  $12.3 \pm 6$ ,  $P < 0.05$ ). There was no difference in C-peptide levels in all groups (Table 2).

#### Effects of ARB on inflammatory risk markers


Plasma adiponectin levels increased significantly in both groups (IGT  $3.2 \pm 1.0$  vs.  $4.1 \pm 1.9$   $\mu$ g/ml,  $P < 0.05$ ; NGT  $5.2 \pm 2.4$  vs.  $6.3 \pm 2.9$ ,  $P < 0.05$ ). hsCRP levels decreased significantly in the IGT group (IGT  $3.9 \pm 1.9$  vs.  $1.8 \pm 0.9$  mg/l,  $P < 0.05$ ; NGT  $1.8 \pm 0.9$  vs.  $2.2 \pm 1.9$ ,  $P = 0.89$ ).

**CONCLUSIONS**— In obese males with IGT, we found increased inflammatory markers associated with a higher degree of insulin resistance compared with

**Table 2**—Insulin resistance parameters, inflammatory markers, and 24-h systolic and diastolic blood pressure of the subjects according to the study groups with and without ARB

	IGT group	NGT group	P	IGT group + ARB	NGT group + ARB
n	13	13		13	13
Adiponectin ( $\mu$ g/ml)	$3.2 \pm 0.9$	$5.2 \pm 2.4$	$<0.05$	$4.1 \pm 1.9^*$	$6.3 \pm 2.9^*$
HOMA-IR	$4.1 \pm 3$	$2.3 \pm 1$	$<0.01$	$2.6 \pm 2^\dagger$	$1.6 \pm 1$
Insulin sensitivity index	$1.5 \pm 0.9$	$1.8 \pm 1.2$	$<0.05$	$2.3 \pm 1^*$	$2.5 \pm 2^*$
Fasting (insulin) (mU/l)	$16.6 \pm 11.2$	$16.1 \pm 10$	$<0.05$	$13.2 \pm 8^*$	$12.3 \pm 6^*$
C-peptide (nmol/l)	$1.2 \pm 0.4$	$1.5 \pm 1$	0.78	$1.0 \pm 0.4$	$1.2 \pm 0.4$
hsCRP (mg/l)	$3.9 \pm 1.9$	$1.8 \pm 1$	$<0.05$	$1.8 \pm 0.9^*$	$2.2 \pm 1.9$
A1C (%)	$5.58 \pm 0.2$	$5.29 \pm 0.2$	$<0.01$	$5.20 \pm 0.3^*$	$5.30 \pm 0.3$
RBP4 (ng/ml)	$27.1 \pm 2.1$	$24.0 \pm 2.0$	$<0.05$	$22.1 \pm 1.8^\dagger$	$22.0 \pm 1.9$
24-h systolic blood pressure (mmHg)	$125 \pm 6$	$123 \pm 1$	0.86	$118 \pm 3^*$	$121 \pm 4$
24-h diastolic blood pressure (mmHg)	$77 \pm 2$	$77 \pm 3$	0.95	$73 \pm 3$	$74 \pm 5$

Data are means  $\pm$  SD, unless otherwise indicated. \* $P < 0.05$ .  $^\dagger P < 0.01$ .



**Figure 3**—Insulin resistance defined by HOMA-IR with and without ARB separately for the NGT and IGT group.

matched obese subjects with NGT. Treatment with valsartan improved insulin sensitivity, RBP4, and A1C as chemical features of insulin resistance. hsCRP and adiponectin improved in the group of subjects with IGT.

**Improvement of insulin sensitivity**

In IGT, defective early-phase and late insulin secretion combined with muscle and hepatic insulin resistance results in prolonged hyperglycemia after a glucose load. Our data confirm pathophysiological mechanisms, where the timeframe after glucose bolus averages about 20 min longer than for the control group. After treatment with valsartan, metabolic changes are indicated by a decrease in insulin resistance and an increase in adiponectin. The reduction of time to reach the targeted blood glucose <180 mg/dl after glucose bolus within the IGT group under ARB demonstrates an improvement in early-phase insulin secretion and reduction of insulin resistance. A sequential insulin scan between glucose bolus and target value is advisable but was not part of this study. Jin and Pan (10) showed an improvement in glucose homeostasis in type 2 diabetic patients by losartan. The results of the Diabetes Reduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial indicated favorable effects of RAS blockade with ramipril on glucose metabolism (11). Mechanisms for the improvement of glucose tolerance are complex. The inter-

action of RAS with peroxisome proliferator-activated receptor (PPAR)- $\gamma$  affects insulin sensitivity (12). Angiotensin II inhibits adipogenic differentiation of human adipocytes via the AT1 receptor (13). Expression of angiotensin II-forming enzymes in adipose tissue correlates inversely with insulin sensitivity by decreased circulating adiponectin (14). In vivo, the activation of the angiotensin 2 receptor and certain ARB induce adiponectin in adipocytes, which is associated with improvement in insulin sensitivity in murine adipocytes and obese Zucker rats. ARB-induced adiponectin stimulation is likely to be mediated via PPAR- $\gamma$  activation involving a posttranscriptional mechanism (15). ARB induce adipogenesis and PPAR- $\gamma$  target gene expression in human adipocytes and increase adiponectin, which contributes to the metabolic impact of this class of drug. In humans, it is unclear whether larger doses of ARB or longer treatments, or both, may be required to activate PPAR- $\gamma$  in adipose cells. The relevance for the glucose metabolism of the PPAR- $\gamma$  agonist actions of the ARB on insulin sensitivity in patients with IGT is unclear, noting that effects are much greater in cell-free systems than in intact cells or in vivo (16). Another mechanism to discuss is improvement of intra-islet blood flow regulated by local activity of the RAS (17). We have no knowledge of any upregulation of the RAS through the temporary hyperglycemia in patients with IGT. In animal testing by the Zucker obese (*fa/fa*) model of type 2 diabetes, an upregulation after glucose load was noted. After administration of an ARB, islet blood flow increased insulin secretion and increased  $\beta$ -cell mass and normalization of islet morphology (18). Changes in islet perfusion may contribute to the delayed first phase of insulin response to glucose. The enhancement of insulin signaling, possibly additionally disturbed by angiotensin II receptor cross-talk and insulin secretion by the  $\beta$ -cells, supports glucose delivery to insulin-sensitive tissue by inhibiting the RAS, which may improve intra-islet blood flow and microcirculation in skeletal muscle.

While in rats Juan et al. (19) demonstrated increased insulin sensitivity upon chronic angiotensin II infusion, we found in contrast increased insulin sensitivity by ARB treatment in human subjects with IGT. We know that angiotensin II exerts its effects through two different receptors, the angiotensin type 1 receptor (AT1R)

and angiotensin type 2 receptor (AT2R). We know that the AT1 receptor is the predominant receptor in the cardiovascular system and mediates most of the deleterious effects of angiotensin II, such as vasoconstriction, endothelial damage, and cell proliferation. The AT2 receptor is now recognized as the counter-regulator of the AT1 receptor, exerting mostly beneficial actions such as vasodilation, anti-proliferation, and anti-inflammatory effects. Apart from species differences, these contradicting results may be explained by the AT2R stimulation during selective AT1 receptor blockade under certain pathological conditions in which the available angiotensin II is redirected to the AT2 receptor.

**Improvement of inflammatory risk markers**

Subclinical low-grade inflammation plays an important role in the pathogenesis of insulin resistance. Angiotensin II adversely affects glucose metabolism by increasing reactive oxygen species and inducing subclinical inflammation. Elevated CRP serum levels have been associated with cardiovascular disease and insulin resistance (20). Adiponectin inhibits production and action of tumor necrosis factor (TNF)- $\alpha$ , which may influence interleukin-6 and CRP production (21). It has been shown that CRP suppresses adiponectin gene expression partially through the phosphatidylinositol 3-kinase pathway, and decreased production of adiponectin might represent a mechanism by which CRP regulates insulin sensitivity (22). Yuan et al. (23) showed an elevation of hsCRP in patients with IGT accompanied by the opposite changes of adiponectin. In our study, treatment with valsartan improved hsCRP and adiponectin concentrations. RBP4 has been shown to correlate with the magnitude of insulin resistance in lean, obese, and diabetic subjects identifying associated cardiovascular risk factors (6). Our data confirm these findings for subjects with IGT with significantly higher RBP4 levels compared with matched control subjects with NGT, indicating possible beneficial effects for the prevention of diabetes.

**Effect of RAS blockade on blood pressure in IGT**

Obesity is a major etiological factor in prehypertension in which adipose tissue activates the RAS. The Trial of Prevention of Hypertension demonstrated



that angiotensin receptor blockade delays blood pressure exaggeration in prehypertensive patients (24). Our study included prehypertensive individuals, defined as having a systolic blood pressure of 120–139 mmHg or diastolic blood pressure of 80–89 mmHg, and hypertensive individuals. The mean reduction in ambulatory systolic blood pressure under valsartan treatment was considerably higher in the IGT group than the NGT group. These changes may reflect an activated RAS in subjects with insulin resistance.

We acknowledge the following limitation of our experimental study: In isolated IGT, the primary pathomechanism is defective early-phase and late insulin secretion combined with muscle and hepatic insulin resistance. An important additional pathomechanism is also the reduced glucagon-like peptide (GLP)-1 serum level (25). In our patient group, we cannot exclude to a certain extent a variance of the low GLP-1 levels. In addition, since we investigated insulin resistance during intravenous glucose stress testing, the effects of incretins (GLP-1, glucose-dependent insulinotropic peptide) on intravenous glucose load were not retrieved. This important and interesting incretin effect has to be taken into account in interpreting our results.

In conclusion, in patients with impaired glucose tolerance, insulin sensitivity and associated low-grade inflammation improve after treatment with ARB. These effects may provide a rationale for early pharmacological intervention aimed at ameliorating diabetic and cardiovascular risk in subjects with metabolic disease.

**Acknowledgments**— This investigator-initiated trial was supported by a grant from Novartis Pharma.

No other potential conflicts of interest relevant to this article were reported.

The extremely valuable contribution of Bernhard Haller (Institute for Medical Statistics and Epidemiology, Technical University Munich) and Renate Bratke (study assistant, Department of Nephrology, Technical University Munich) is gratefully acknowledged.

**References**

1. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with

diabetes compared with non-diabetic people: a population-based retrospective cohort study. *Lancet* 2006;368:29–36

2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2007;30:42–47

3. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;288:2709–2716

4. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. *J Clin Endocrinol Metab* 2004;89:2563–8256

5. Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, Kamon J, Kobayashi M, Suzuki R, Hara K, Kubota N, Terauchi Y, Froguel P, Nakae J, Kasuga M, Accili D, Tobe K, Ueki K, Nagai R, Kadowaki T. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. *J Biol Chem* 2004;279:30817–30822

6. Graham TE, Yang Q, Blueher M, Hammarstedt A, Ciaraldi TP, Henry RR, Watson CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. *N Engl J Med* 2006;354:2552–2563

7. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol* 1979;237:E214–E223

8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412–419

9. Hanson RL, Pratley RE, Bogadus C, Narayan KM, Roumain JM, Imperatore G, Fagot-Campagna A, Pettitt DJ, Bennett PH, Knowler WC. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. *Am J Epidemiol* 2000;151:190–198

10. Jin HM, Pan Y. Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. *Nephrol Dial Transplant* 2007;22:1943–1949

11. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. *Lancet* 2006;368:1096–1105

12. Kurtz TW. New treatment strategies for patients with hypertension and insulin resistance. *Am J Med* 2006;119(Suppl. 1):S24–S30

13. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. *Diabetes* 2002;51:1699–1707

14. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. *J Hypertens* 2002;20:965–973

15. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thöne-Reineke C, Unger T, Kintscher U. PPAR-gamma-activating angiotensin type-1 receptor blockers induce adiponectin. *Hypertension* 2005;46:137–143

16. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPAR-gamma by angiotensin II type 1-receptor antagonists. *Vascul Pharmacol* 2006;45:154–162

17. Jansson L. The regulation of pancreatic islet blood flow. *Diabete Metab Rev* 1994;10:407–416

18. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improvement islet morphology after blockade of the renin-angiotensin system in the ZDF rat. *Diabetes* 2004;53:989–997

19. Juan CC, Chien Y, Wu LY, Yang WM, Chang CL, Lai YH, Ho PH, Kwok CF, Ho LT. Angiotensin II enhances insulin sensitivity in vitro and in vivo. *Endocrinology* 2005;146:2246–2254

20. Dehghan A, Kardys I, de Maat MPM, Uitterlinden AG, Sijbrands EJG, Bootsma AH, Stijnen T, Hofman A, Schram MT, Witteman JCM. Genetic variation, C-reactive protein levels, and incidence of diabetes. *Diabetes* 2007;56:872–878

21. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. *Circulation* 2001;103:1057–1063

22. Yuan G, Chen X, Ma Q, Qiao J, Li R, Li X, Li S, Tang J, Zhou L, Song H, Chen M. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. *J Endocrinol* 2007;194:275–281

23. Yuan G, Zhou L, Tang J, Yang Y, Gu W, Li F, Hong J, Gu Y, Li X, Ning G, Chen M. Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity.

- Diabetes Res Clin Pract 2006;72:244–250
24. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. *N Engl J Med* 2006;354:1685–1697
25. Laakso M, Zilinskaite J, Hansen T, Boesgaard TW, Vanttinen M, Sancáková A, Jansson PA, Pellmé F, Holst JJ, Kuulasmaa T, Hribal ML, Sesti G, Stegán N, Fritsche A, Häring H, Pedersen O, Smith U. EUGENE2 Consortium. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. *Diabetologia* 2008;51:502–511